Indefinite Delivery Contract SPE2DB24D9228

This single-award indefinite delivery contract with a potential value of up to $499,999,999 was awarded to DMS Pharmaceutical Group Inc., a for-profit, woman-owned small business, by the Defense Logistics Agency. The contract, under the SPE2DB program, enables the DLA to issue firm fixed-price delivery orders through December 31, 2025 for a broad range of pharmaceutical products to support the recurring medical supply needs of military health facilities globally. Major categories of goods to be delivered include prescription drugs, over-the-counter medications, biologics, and other medical supplies such as naltrexone tablets, botulinum toxin injections, chemotherapy drugs, HIV antiretrovirals, ophthalmic solutions, injectable anesthetics, and a variety of generic pharmaceuticals. This IDV complements DMS Pharmaceutical Group's existing prime vendor contracts for direct pharmaceutical distribution and pharmacy services to the Department of Defense. The contract has no set-aside designation, but DMS's woman-owned small business status has enabled direct federal contract awards for supporting military medical facilities through the Defense Logistics Agency's pharmaceutical supply programs.